Alpha Cognition (OTC:ACOGF) and Revolution Medicines (NASDAQ:RVMD) Head to Head Contrast

Alpha Cognition (OTC:ACOGF) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Insider and Institutional Ownership

94.3% of Revolution Medicines shares are owned by institutional investors. 31.5% of Alpha Cognition shares are owned by insiders. Comparatively, 8.0% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Alpha Cognition and Revolution Medicines, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0	0	0	0	0.00
Revolution Medicines	0	0	11	1	3.08

Revolution Medicines has a consensus target price of $66.25, suggesting a potential upside of 61.62%. Given Revolution Medicines’ stronger consensus rating and higher possible upside, analysts plainly believe Revolution Medicines is more favorable than Alpha Cognition.

Risk & Volatility

Alpha Cognition has a beta of 2.8, suggesting that its stock price is 180% more volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.

Profitability

This table compares Alpha Cognition and Revolution Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	N/A	N/A	-522.43%
Revolution Medicines	N/A	-33.67%	-30.08%

Valuation and Earnings

This table compares Alpha Cognition and Revolution Medicines”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	N/A	N/A	-$13.77 million	C($0.12)	N/A
Revolution Medicines	$11.58 million	595.45	-$436.37 million	($3.59)	-11.42

Alpha Cognition has higher earnings, but lower revenue than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Summary

Revolution Medicines beats Alpha Cognition on 7 of the 12 factors compared between the two stocks.

About Alpha Cognition

Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

About Revolution Medicines

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company’s RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.